Growth attenuation therapy: practice and perspectives of paediatric endocrinologists

The demonstration here that approximately one in three responding paediatric endocrinologists have been asked about GAT for a child with SPCD provides an opportunity for further investigation regarding efficacy of GAT in length reduction, quality of life improvement and the possible risks of therapy...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2015-12, Vol.100 (12), p.1185-1185
Main Authors: Pollock, Allison J, Fost, Norman, Allen, David B
Format: Article
Language:English
Subjects:
Child
Child Development - drug effects
Childhood Interests
Children & youth
Collaboration
Disabled Children
Endocrinology
Ethics
Family (Sociological Unit)
Humans
Patient Transfer - methods
Pediatrics
Physicians
Practice Patterns, Physicians
Quality of life
Questionnaires
Response rates
Response Rates (Questionnaires)
Statistical Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The demonstration here that approximately one in three responding paediatric endocrinologists have been asked about GAT for a child with SPCD provides an opportunity for further investigation regarding efficacy of GAT in length reduction, quality of life improvement and the possible risks of therapy. 3 The main limitations of this study were (1) brevity of the questionnaire, which was designed to optimise ease of participation and therefore maximise the response rate and (2) the possibility that respondents may not be representative of paediatric endocrinologists overall. [...]paediatric endocrinologists are receiving inquiries regarding GAT from families of children with SPCD more commonly than previously realised and at least 65 children with SPCD have received GAT.
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2015-309130